VIRIDIAN THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 96
- Market Cap
- -
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: VRDN-003Drug: Placebo
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06625411
- Locations
- 🇺🇸
Marvel Clinical Research, Huntington Beach, California, United States
🇺🇸United Medical Research Institute, Inglewood, California, United States
🇺🇸Pasadena Clinical Trials, Pasadena, California, United States
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: VRDN-003Drug: Placebo
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT06625398
- Locations
- 🇺🇸
Marvel Clinical Research, Huntington Beach, California, United States
🇺🇸United Medical Research Institute, Inglewood, California, United States
🇺🇸Pasadena Clinical Trials, Pasadena, California, United States
A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: VRDN-001 10 mg/kgDrug: VRDN-001 3 mg/kg
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT06384547
- Locations
- 🇺🇸
Central Coast Retina, Santa Maria, California, United States
🇺🇸United Medical Research Institute, Inglewood, California, United States
🇺🇸Med-Care Research Corp., Miami, Florida, United States
An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: Intervention/Treatment
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT06179875
- Locations
- 🇺🇸
MACRO Trials, Inc., Los Angeles, California, United States
🇺🇸Rutgers New Jersey Medical School, Newark, New Jersey, United States
🇺🇸Amy Patel Jain, MD Inc, Newport Beach, California, United States
A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: Veligrotug (VRDN-001)Drug: Placebo
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT06021054
- Locations
- 🇹🇷
Gazi University Medical Faculty Hospital, Ankara, Turkey
🇹🇷Akdeniz University Medical Faculty Hospital, Antalya, Turkey
🇹🇷Marmara University Faculty of Medicine, Istanbul, Turkey
A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)
- Conditions
- Thyroid Eye Disease
- Interventions
- Drug: Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED)Drug: VRDN-001 Phase 3 Cohort (THRIVE)Drug: VRDN-001 Placebo
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT05176639
- Locations
- 🇫🇷
Hospital Lapeyronie, Montpellier, France
🇪🇸Hospital Universitario Ramon y Cajal. Ctra. de Colmenar,, Madrid, Spain
🇺🇸The Private Office of Raymond Douglas, Beverly Hills, California, United States